Community Acquired Pneumonia: An Update on Guidelines
|
|
- Patrick Johns
- 6 years ago
- Views:
Transcription
1 Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006
2 Objectives To give a brief description of the pathophysiology of community acquired pneumonia (CAP) To discuss the various organisms that cause CAP To discuss the clinical settings with increased risk of pathogens To show which drugs treat CAP bugs To compare the old MSH guidelines to the new MSH guidelines To show evidence supporting these changes To compare side effects, drug interactions, convenience, and cost of the various antibiotics used to treat CAP
3 Pathophysiology Organisms can gain access to the lower respiratory tract via: o o o inhalation, bloodstream aspiration Changes in the pulmonary defence may increase the likelihood of infection: Cough reflex can be impaired by stroke, neuromuscular disease, sedatives, s or poor nutrition Mucociliary transport is depressed with the aging process, tobacco smoking, dehydration, morphine, atropine, prior infection with influenza virus, and chronic bronchitis. Anatomic changes such as emphysema, bronchiectasis,, and obstructive mass lesions prevent clearance of microbes.
4 Organisms Causing CAP Streptococcus Pneumoniae Haemophilus influenzae Mycoplasma pneumoniae Chlamydia pneumoniae Other agents include: S. aureus,, group A streptococci, Moraxella catarrhalis, Legionella species, Gram negative bacilli, anaerobes, and viruses, including respiratory syncytial virus, influenza virus, and parainfluenza virus.
5 Clinical Settings with Increased Risk of Pathogens Alcoholism anaerobes, gram-negative bacilli COPD/smoker H. influenzae, M. catarrhalis Increased age/co-morbid medical conditions Gram negative bacilli Recent hospitalizations Gram negative bacilli, S. aureus, Legionella species, anaerobes Nursing home Gram negative bacilli, H. influenzae, S. aureus, C. pneumoniae, anaerobes
6 DRUGS that fight CAP BUGS Macrolides S. pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella species (azithromycin( and clarithromycin), H. influenzae (azithromycin and clarithromycin) Fluoroquinolones S. pneumoniae, Legionella species, H. influenzae Amoxicillin, Amoxicillin/Clavulanic acid S. pneumoniae, Moraxella catarrhalis or H. influenzae 2 nd or 3 rd generation cephalosporins S. pneumoniae,, aerobic gram negative bacilli, H. influenzae Clindamycin S. pneumoniae, anaerobes Metronidazole anaerobes
7 Outpatient Therapy Without Modifying Factors OLD GUIDELINES Erythromycin 500mg PO q6h Azithromycin 500mg PO on day 1, then 250mg PO od f4d Clarithromycin 500mg PO q12h NEW GUIDELINES Azithromycin 500mg PO on day 1, then 250mg PO od f4d Clarithromycin 500mg PO q12h Clarithromycin XL 1000mg PO od * Alternative: Doxycycline 100mg PO q12h Alternative: Doxycycline 100mg PO q12h Moxifloxacin 400mg PO od Levofloxacin mg PO od * = Non-formulary
8 Outpatient Therapy With Modifying Factors OLD GUIDELINES Amoxicillin/clavulanic clavulanic acid 500mg/125mg PO q8h Cefuroxime 500mg PO q12h Cefprozil 500mg PO q12h One of the above plus: Azithromycin 500mg PO on day 1, then 250mg PO od f4d Clarithromycin 500mg PO q12h Single Therapy: Levofloxacin 500mg PO od Moxifloxacin 400mg PO od NEW GUIDELINES Amoxicillin/clavulanic clavulanic acid 875mg/125mg PO q12h * Amoxicillin/clavulanic clavulanic acid 500mg/125mg PO q8h Amoxicillin 1000mg PO q8h One of the above plus: Azithromycin 500mg PO on day 1, then 250mg PO od f4d Clarithromycin 500mg PO q12h Clarithromycin XL 1000mg PO daily * Single Therapy: Levofloxacin mg PO od Moxifloxacin 400mg PO od
9 Inpatient Therapy Admission to a Hospital Ward OLD GUIDELINES AL Amoxicillin/clavulanic clavulanic acid 500mg125mg PO q8h Plus Azithromycin 500mg PO on day 1, then 250mg PO od f4d Clarithromycin 500mg PO q12h Single Therapy: Levofloxacin 500mg PO od NEW GUIDELINES AL Amoxicillin/clavulanic clavulanic acid 875mg/125mg PO q12h * Amoxicillin/clavulanic clavulanic acid 500mg/125mg PO q8h Amoxicillin 1000mg PO q8h Plus Azithromycin 500mg PO on day 1, then 250mg PO od f4d Clarithromycin 500mg PO q12h Clarithromycin XL 1000mg PO od * INTRAVENOUS Ceftriaxone 1g IV q24h plus Azithromycin 500mg IV od f5d Levofloxacin 500mg IV od Single Therapy: Moxifloxacin 400mg PO od INTRAVENOUS Ceftriaxone 1g IV q24h plus Azithromycin 500mg IV od f5d Moxifloxacin 400mg IV od
10 Inpatient Therapy Macro- Aspiration OLD GUIDELINES AL Amoxicillin/clavulanic clavulanic acid 500mg/125mg PO q8h INTRAVENOUS Ceftriaxone 1g IV q24h with Metronidazole 500mg IV q12h NEW GUIDELINES AL Amoxicillin/clavulanic clavulanic acid 875mg/125mg PO q12h * Amoxicillin/clavulanic clavulanic acid 500mg/125mg PO q8h INTRAVENOUS Ceftriaxone 1g IV q24h with Metronidazole 500mg IV q12h
11 Inpatient Therapy: Admission to an ICU OLD GUIDELINES Ceftriaxone 1g IV q24h with Azithromycin 500mg IV od NEW GUIDELINES Ceftriaxone 1g IV q24h with Azithromycin 500mg IV od Alternative: Ceftriaxone 1g IV q24h with Levofloxacin 500mg IV/PO od Alternative: Ceftriaxone 1g IV q24h with Moxifloxacin 400mg IV/PO od
12 Inpatient Therapy Admission to an ICU (Modifying Factors) OLD GUIDELINES Bronchiectasis Piperacillin/Tazobactam 4.5g IV q8h with Tobramycin 5mg/kg IV od NEW GUIDELINES Bronchiectasis Piperacillin/Tazobactam 4.5g IV q8h with Ciprofloxacin 400mg IV/750mg PO q12h Suspected or confirmed Pseudomonas aeruginosa: Piperacillin/Tazobactam 4.5g IV q8h with Tobramycin 5mg/kg IV od PLUS Azithromycin 500mg IV od or Levofloxacin 500mg IV od Suspected or confirmed Pseudomonas aeruginosa: Piperacillin/Tazobactam 4.5g IV q8h with Tobramycin 5mg/kg IV od PLUS Azithromycin 500mg IV od or Moxifloxacin 400mg IV/PO od
13 Evidence For Addition of High Dose Amoxicillin Aubier M, Verster C, Regamey P, et al. Once-Daily Sparfloxacin Versus High Dosage Amoxicillin in the Treatment of Community-Acquired, Suspected Pneumococcal Pneumonia in Adults.. Clinical Infectious Disease. 1998; 26: One year, multi-center, randomized, double- blind trial comparing the efficacy and safety of once-daily sparfloxacin and a 1-g 1 tid dosage of amoxicillin Out of 329 enrolled patients, 159 were randomized to receive sparfloxacin and 170 to receive amoxicillin
14 Evidence for Addition of High Dose RESULTS: Amoxicillin /2 Average duration was 10.8 days Both drugs were effective in the intent-to to-treat treat and evaluable population at both endpoints Overall rates of success among evaluable patients were equivalent between drugs, both at the end of treatment (sparfloxacin( sparfloxacin,, 92%; amoxicillin, 87%) and at follow-up (sparfloxacin( sparfloxacin,, 89%; amoxicillin, 84%) Sparfloxacin was well tolerated and produced fewer gastrointestinal side effects than amoxicillin
15 Resistance of Fluoroquinolones Emergence of S. pneumoniae with reduced susceptibility to the fluoroquinolones (FQ) has been described in Canada, Spain, Hong Kong, eastern and central Europe and to a lesser extent, the United States Resistance is primarily due to mutations in the genes encoding the target topoisomerase enzymes In Canada, Chen et al found that ciprofloxacin-resistant resistant pneumococci increased from 0% in 1993 to 1.7% in In adults the prevalence was 0% in 1993 to 3.7% in 1998 In 2002, the Canadian Bacterial Surveillance Network reported a prevalence of levofloxacin-resistant pneumococci of 4% in sputum isolates recovered from patients over 65 years of age
16 Evidence for High Dose, Short Course Levofloxacin Dunbar LM, Wunderink RG, Habib MP, et al. High-Dose, Short- Course Levofloxacin for Community-Acquired Pneumonia: A New Treatment Paradigm. Clinical Infectious Diseases. 2003; 37: Multi-center, randomized, double-blind blind trial Compared levofloxacin dosages of 750mg/ day for 5 days with 500mg/day for 10 days for the treatment of mild to severe CAP Out of 530 patients enrolled, 256 patients received levofloxacin 750mg/day IV/PO for 5 days and 272 patients received levofloxacin 500mg/day IV/PO for 10 days
17 Evidence for High Dose, Short Results: Course Levofloxacin /2 At post-therapy therapy assessment, the clinical success rates in the clinically evaluable population were 92.4% for the 750mg group and 91.1% for the 500mg group Microbiological eradication rates were 93.2% and 92.4% in the 750mg and 500mg groups, respectively. Authors concluded that the short course, high dose regimen of levofloxacin was at least as effective and well tolerated for the treatment of mild to severe CAP as 500mg of levofloxacin per day for 10 days.
18 Side Effects and Drug Interactions of the Various Antibiotics Macrolides Side effects include: abdominal cramping, nausea, vomiting, diarrhea,, rash Drug interactions include: warfarin, digoxin,, cyclosporine, benzodiazepines, carbamezapine Doxycycline Side effects include: nausea, vomiting, photosensitivity Drug interactions include: calcium, magnesium, iron, phenytoin, phenobarbital Amoxicillin, Amoxicillin/Clavulanic acid Side effects include: hypersensitivity reactions, rash, nausea, vomiting Fluoroquinolones Side effects include: abdominal pain, headache, dizziness, photosensitivity Drug interactions include: calcium, warfarin, theophylline, cyclosporine Ceftriaxone Side effects include: hypersensitivity reactions, rash, nausea, vomiting, pain at the injection site Metronidazole Side effects include: vertigo, headache, abdominal cramps, diarrhea,, vomiting, taste alterations Drug interactions include: ethanol, warfarin
19 Convenience and Cost of the Various Antibiotics Macrolides Dosing: QID (E), BID (C), OD (A and C) Cost: E - $0.80 A - $3.52 (PO), $20.50 (IV) C - $5.92 Doxycycline Dosing: BID Cost: $0.56 Amoxicillin, Amoxicillin/Clavulanic acid Dosing: BID, TID Cost: $0.66 (A) $1.56 (A/C) Fluoroquinolones Dosing: BID (C), OD (M, L) Cost: C - $1.22 (PO), $57.02 (IV) M - $3.40 (PO), $28.90 (IV) L - $4.00 (500mg PO), $7.55 (750mg PO), $34.00 (IV) Ceftriaxone Dosing: OD Cost: $34.00 Metronidazole Dosing: BID Cost: $0.44 (PO), $2.58 (IV) Cost in terms of per day
20 References 1. Mandell LA, Bartlett JG, et al. Update of the Infectious Diseases of Society S of America Guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clinical Infectious Diseases. 2003; 37: Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community acquired pneumonia: an evidence-based update by the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clinical Infectious Diseases. 2000; 31: University Health Network. Guidelines for Antimicrobial Use. Antibiotic A Subcommittee of the Pharmacy and Therapeutics Committee. Revised Feb University Health Network. Guidelines for Antimicrobial Use. Antibiotic Subcommittee of the Pharmacy and Therapeutics Committee. Revised Sept Chen D, McGeer A, de Azevedo J et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillanc Network. New England Journal of Medicine. 1999; 341: Aubier M, Verster R, Regamey C, et al. Once-daily sparfloxacin versus high dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clinical Infectious Diseases ; 26: Dunbar LM, Wunderink RG, Habib MP, et al. High-Dose, Short-Course Levofloxacin for Community-Acquired Pneumonia: A New Treatment Paradigm. Clinical Infectious Diseases. 2003; 37: Marrie TJ. Community-acquired Pneumonia. In: Gray, J. Therapeutic Choices. Ottawa: Canadian Pharmacists Association; 2003: Wells BG, DiPiro JT, Schwinghammer TL, Hamilton CW. Respiratory Tract Infections, Lower. In: Pharmacotherapy Handbook 6 th Edition. New York: McGraw-Hill Publishing; 2006:
GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationAntibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationAZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES
AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics
More informationFluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do?
Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More informationPrescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children
Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More information10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally
Low: not well absorbed PO agent not for serious infection nitrofurantoin Good: [blood and tissue] < than if given IV [Therapeutic] in excess of [effective] eg. cephalexin High: > 90% absorption orally
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationCME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationPerichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
More informationControl emergence of drug-resistant. Reduce costs
...PRESENTATIONS... Guidelines for the Management of Community-Acquired Pneumonia Richard E. Chaisson, MD Presentation Summary Guidelines for the treatment of community-acquired pneumonia (CAP) have been
More informationAminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.
Aminoglycosides The only bactericidal protein synthesis inhibitors. They bind to the ribosomal 30S subunit. Inhibit initiation of peptide synthesis and cause misreading of the genetic code. Streptomycin
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationAntibiotics Use And Concordance To Guidelines For Patients Hospitalized With Community Acquired Pneumonia (CAP)
Antibiotics Use And Concordance To Guidelines For Patients Hospitalized With Community Acquired Pneumonia (CAP) SF Teoh 1, Samsinah Hussain 1, CK Liam 2 1 Departments of Pharmacy, Faculty of Medicine,
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationSafety of an Out-Patient Intravenous Antibiotics Programme
Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationLifting the lid off CAP guidelines
Lifting the lid off CAP guidelines Dr. Andrew M. Morris September 5, 2007 12:00-13:00 web.mac.com/idologist Objectives 1. To review the epidemiology of community-acquired pneumonia (CAP) 2. To explore
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationBai-Yi Chen MD. FCCP
Treatment strategies for hospitalized versus nonhospitalized CAP patients: Asian perspective Bai-Yi Chen MD. FCCP Professor of Medicine Division of Infectious Disease, Infection Control Team The First
More informationCLINICAL USE OF BETA-LACTAMS
CLINICAL USE OF BETA-LACTAMS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu WHY IS INFECTIOUS DISEASE PHARMACOTHERAPY SO CONFUSING? Microbial
More information3/23/2017. Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc. Kathryn G. Smith: Nothing to disclose
Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc Kathryn G. Smith: Nothing to disclose Describe the new updates and rationale for them Relay safety concerns with use of
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationAntimicrobial Update Stewardship in Primary Care. Clare Colligan Antimicrobial Pharmacist NHS Forth Valley
Antimicrobial Update Stewardship in Primary Care Clare Colligan Antimicrobial Pharmacist NHS Forth Valley Setting the Scene! Consequences of Antibiotic Use? Resistance For an individual patient with
More informationProvincial Drugs & Therapeutics Committee Memorandum Version 2
Provincial Drugs & Therapeutics Committee Memorandum Version 2 16 Garfield Street 16, rue Garfield PO Box 2000, Charlottetown C.P. 2000, Charlottetown Prince Edward Island Île-du-Prince-Édouard Canada
More informationHealth PEI: Provincial Antibiotic Advisory Team Empiric Antibiotic Treatment Guidelines for Sepsis Syndromes in Adults
Health PEI: Provincial Antibiotic Advisory Team Empiric Antibiotic Treatment Guidelines for Sepsis Syndromes in Adults COMMUNITY-ACQUIRED PNEUMONIA HEALTHCARE-ASSOCIATED PNEUMONIA INTRA-ABDOMINAL INFECTION
More informationAntimicrobial Stewardship in Ambulatory Care
Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative
More informationRational management of community acquired infections
Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?
More informationPharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only
Last Updated: Version 4.4a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Collected For: CMS Voluntary
More informationUpdated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007
Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 1 Ongoing data from CDC 's Gonococcal Isolate Surveillance Project (GISP), including
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationIMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationORIGINAL INVESTIGATION. Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia
ORIGINAL INVESTIGATION Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia Reba K. Ailani, MD; Gautami Agastya, MD; Rajesh K. Ailani, MD; Beejadi N. Mukunda,
More informationORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA
ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Vicks Vapo Rub for Cold Symptoms
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Vicks VapoRub
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationand Health Sciences, Wayne State University and Detroit Receiving Hospital, Detroit, MI, USA
Journal of Antimicrobial Chemotherapy (2004) 54, Suppl. S1, i7 i15 DOI: 10.1093/jac/dkh313 JAC Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationObjectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More informationReport on New Patented Drugs - Ketek
Report on New Patented Drugs - Ketek October 2006 Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB
More informationWomen s Antimicrobial Guidelines Summary
Women s Antimicrobial Guidelines Summary 1. Introduction and Who Guideline applies to This guideline has been developed to deliver safe and appropriate empirical use of antibiotics for patients at University
More informationLet me clear my throat: empiric antibiotics in
Let me clear my throat: empiric antibiotics in respiratory tract infections Alexander John Langley, MD MS MPH Goals of this talk Overuse of antibiotics is a major issue, as a result many specialist medical
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationSEPTEMBER 2017 DRUG ANTIBIOTICS COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
SEPTEMBER 2017 DRUG ANTIBIOTICS This optimal usage guide is mainly intended f primary care health professionnals. It is provided f infmation purposes only and should not replace the clinician s judgement.
More informationChoosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections
...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Vicks VapoRub
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationPneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationNational Antimicrobial Prescribing Survey
Indication documented Surgical prophylaxis >24 hrs Allergy mismatch Microbiology mismatch Incorrect route Incorrect dose/frequency Incorrect duration Therapeutic Guidelines Local guidelines * Non-compliant
More informationInfection Comments First Line Agents Penicillin Allergy History of multiresistant. line treatment: persist for >7 days they may be
Gastrointestinal Infections Infection Comments First Line Agents Penicillin Allergy History of multiresistant Campylobacter Antibiotics not recommended. Erythromycin 250mg PO 6 Alternative to first N/A
More informationCommunity-acquired pneumonia: Time to place a CAP on length of treatment?
LOGIN TO LEARN: An Engaging and Interactive Journal Club for Pharmacists and Students Community-acquired pneumonia: Time to place a CAP on length of treatment? Jennifer Ball, PharmD Learning Objectives
More informationInfection. Recently introduced antibiotics: a guide for the general physician CME: CLINICAL PRACTICE AND ITS BASIS. Linezolid.
CME: CLINICAL PRACTICE AND ITS BASIS Infection Edited by Andrew Lever MD FRCP, Professor of Infectious Diseases Addenbrooke s Hospital, Cambridge Recently introduced antibiotics: a guide for the general
More informationTelephone Clindamycin iv to oral conversion P.O. Box 189 Navan, ON, K4B 1J4 Canada. Sitemap
Telephone 613-835-9490 Clindamycin iv to oral conversion P.O. Box 189 Navan, ON, K4B 1J4 Canada Sitemap 12-3-2018 Healthy people commonly aspirate small amounts of oral secretions, but normal defense mechanisms
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationDoxycycline for strep pneumonia
Doxycycline for strep pneumonia Antibiotic Levofloxacin (Levaquin) 750 mg, 500 mg for the treatment of respiratory, skin, and urinary tract infections, user reviews and ratings. 14-12-1995 John G. Bartlett,
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationCLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:
CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by
More informationResistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints
...PRESENTATIONS... Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints Angela B. Brueggemann, MS; and Gary V. Doern, PhD Presentation Summary Streptococcus pneumoniae
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality
More informationWhat is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa.
Pneumonia What is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa www.netmedicine.com/xray/xr.htm Definition acute infectious disease, etiology usually
More informationOptimising antibiotic policies in the Netherlands, part VIII. Revised SWAB Guidelines for antimicrobial therapy of Community-acquired pneumonia
Optimising antibiotic policies in the Netherlands, part VIII Revised SWAB Guidelines for antimicrobial therapy of Community-acquired pneumonia Dutch Working Party on Antibiotic Policy (SWAB), April 2005
More informationCommunity-Acquired Pneumonia (CAP)
Community-Acquired Pneumonia (CAP) Infectious Diseases Advisory Board 14/01/2000 - Woluwé St Lambert Colloquium Longartsen - 11/02/2000 Dr Yvan Valcke Belgian guidelines on the initial diagnostic and therapeutic
More informationInPHARMation. Pharmacy and Therapeutics Committee Update May 23 rd, 2018 Meeting
VOLUME FOUR; ISSUE 5 May 23, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update May 23 rd, 2018 Meeting The Pharmacy and Therapeutics Committee
More informationORIGINAL INVESTIGATION. Antibiotic Therapy for Ambulatory Patients With Community-Acquired Pneumonia in an Emergency Department Setting
Antibiotic Therapy for Ambulatory Patients With Community-Acquired Pneumonia in an Emergency Department Setting Christine Malcolm, BSc; Thomas J. Marrie, MD ORIGINAL INVESTIGATION Background: Little attention
More informationTreatment of community-acquired lower respiratory tract infections in adults
Eur Respir J 2002; 20: Suppl. 36, 40s 53s DOI: 10.1183/09031936.02.00309002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0904-1850 Treatment of community-acquired
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationSuggested treatment. Inj Crystalline Penicillin 50,000U/Kg i.v. 4-6hrly (if child cannot swallow) 40mg/Kg/dose BID x 10days
GUIDELINES FOR TREATMENT OF INFECTIONS IN CHILDREN A. RESPIRATORY TRACT INFECTIONS UPPER RESPIRATORY TRACT INFECTIONS Infection/Condition/likely organism Suggested treatment Preferred Alternative Acute
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationCommunity Acquired Pneumonia. Epidemiology: Acute Lower Respiratory Tract Infections. Community Acquired Pneumonia (CAP) Outline
Community Acquired Pneumonia (CAP) Outline Lisa G. Winston, MD University of California, San Francisco Zuckerberg San Francisco General Epidemiology Diagnosis Microbiology Risk stratification Treatment
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationAntimicrobial treatment of community acquired pneumonia in adults: A conference report
CONSENSUS CONFERENCE Antimicrobial treatment of community acquired pneumonia in adults: A conference report THE CANADIAN COMMUNITY ACQUIRED PNEUMONIA CONSENSUS CONFERENCE GROUP C OMMUNLTY ACQUIRED PNEUMONI
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationKeywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing
Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review
More informationAntibiotics & Common Infections: Stewardship, Effectiveness, Safety & Clinical Pearls. Welcome We will begin shortly.
Antibiotics & Common Infections: Stewardship, Effectiveness, Safety & Clinical Pearls Welcome We will begin shortly. The Canadian Pharmacists Association is pleased to be collaborating with the following
More informationCommunity Acquired Pneumonia (CAP)
Community Acquired Pneumonia (CAP) The following guidelines have been developed to aid clinicians in the investigation and management of patients with CAP at the Royal Liverpool University Hospital (RLUH).
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationPharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J
Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation
More informationAntibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More information9/9/2015. Disclosure / Contact. Pneumonia Stats. Exploring the Clinical and Regulatory Impact of Pneumonia in Long Term Care
Exploring the Clinical and Regulatory Impact of Pneumonia in Long Term Care Rob Shulman R.Ph. CGP FASCP Director of Consulting Services Remedi SeniorCare William M. Vaughan,RN, BSN Vice President, Education
More information